Breast cancer brain metastasis: molecular mechanisms and directions for treatment

被引:89
作者
Pedrosa, Rute M. S. M. [1 ]
Mustafa, Dana A. [1 ]
Soffietti, Riccardo [2 ,3 ]
Kros, Johan M. [1 ]
机构
[1] Erasmus MC, Dept Pathol, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands
[2] Univ Turin, Dept Neurooncol, Turin, Italy
[3] City Hlth & Sci Hosp, Turin, Italy
关键词
brain metastasis; breast cancer; blood-brain barrier; chemotherapy; molecular mechanisms; LAPATINIB PLUS CAPECITABINE; TRASTUZUMAB EMTANSINE T-DM1; SOLID TUMORS; PHASE-II; MATRIX METALLOPROTEINASES; RESPONSE ASSESSMENT; CELL-MIGRATION; IN-VIVO; EXPRESSION; GROWTH;
D O I
10.1093/neuonc/noy044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of brain metastasis (BM) of breast cancer is usually a late event with deleterious effect on the prognosis. Treatment options for intracerebral seeding of breast cancer are limited and, so far, nonspecific. Molecular detailing of subsequent events of penetration, seeding, and outgrowth in brain is highly relevant for developing therapeutic strategies to treat, or prevent, BM. We scrutinize recent literature for molecules and pathways that are operative in the formation of breast cancer BM. We also summarize current data on therapeutic efforts to specifically address BM of breast cancer. Data on molecular pathways underlying the formation of BM of breast cancer are sketchy and to some extent inconsistent. The molecular makeup of BM differs from that of the primary tumors, as well as from metastases at other sites. Current efforts to treat breast cancer BM are limited, and drugs used have proven effects on the primary tumors but lack specificity for the intracerebral tumors. More basic research is necessary to better characterize BM of breast cancer. Apart from the identification of drug targets defined by the intracerebral tumors, also targets in the molecular pathways involved in passing the blood-brain barrier and intracerebral tumor cell growth should be revealed.
引用
收藏
页码:1439 / 1449
页数:11
相关论文
共 107 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases [J].
Anders, Carey ;
Deal, Allison M. ;
Abramson, Vandana ;
Liu, Minetta C. ;
Storniolo, Anna M. ;
Carpenter, John T. ;
Puhalla, Shannon ;
Nanda, Rita ;
Melhem-Bertrandt, Amal ;
Lin, Nancy U. ;
Marcom, P. Kelly ;
Van Poznak, Catherine ;
Stearns, Vered ;
Melisko, Michelle ;
Smith, J. Keith ;
Karginova, Olga ;
Parker, Joel ;
Berg, Jonathan ;
Winer, Eric P. ;
Peterman, Amy ;
Prat, Aleix ;
Perou, Charles M. ;
Wolff, Antonio C. ;
Carey, Lisa A. .
BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (03) :557-566
[3]   Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain [J].
Avraham, Hava Karsenty ;
Jiang, Shuxian ;
Fu, Yigong ;
Nakshatri, Harikrishna ;
Ovadia, Haim ;
Avraham, Shalom .
JOURNAL OF PATHOLOGY, 2014, 232 (03) :369-381
[4]   Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial [J].
Awada, Ahmad ;
Colomer, Ramon ;
Inoue, Kenichi ;
Bondarenko, Igor ;
Badwe, Rajendra A. ;
Demetriou, Georgia ;
Lee, Soo-Chin ;
Mehta, Ajay O. ;
Kim, Sung-Bae ;
Bachelot, Thomas ;
Goswami, Chanchal ;
Deo, Suryanarayan ;
Bose, Ron ;
Wong, Alvin ;
Xu, Feng ;
Yao, Bin ;
Bryce, Richard ;
Carey, Lisa A. .
JAMA ONCOLOGY, 2016, 2 (12) :1557-1564
[5]   Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study [J].
Bachelot, Thomas ;
Romieu, Gilles ;
Campone, Mario ;
Dieras, Veronique ;
Cropet, Claire ;
Dalenc, Florence ;
Jimenez, Marta ;
Le Rhun, Emilie ;
Pierga, Jean-Yves ;
Goncalves, Anthony ;
Leheurteur, Marianne ;
Domont, Julien ;
Gutierrez, Maya ;
Cure, Herve ;
Ferrero, Jean-Marc ;
Labbe-Devilliers, Catherine .
LANCET ONCOLOGY, 2013, 14 (01) :64-71
[6]   Targeting selectins and selectin ligands in inflammation and cancer [J].
Barthel, Steven R. ;
Gavino, Jacyln D. ;
Descheny, Leyla ;
Dimitroff, Charles J. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (11) :1473-1491
[7]   Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer [J].
Bartsch, Rupert ;
Rottenfusser, Andrea ;
Wenzel, Catharina ;
Dieckmann, Karin ;
Pluschnig, Ursula ;
Altorjai, Gabriela ;
Rudas, Margaretha ;
Mader, Robert M. ;
Poetter, Richard ;
Zielinski, Christoph C. ;
Steger, Guenther G. .
JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (03) :311-317
[8]   Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression [J].
Bengsch, F. ;
Buck, A. ;
Guenther, S. C. ;
Seiz, J. R. ;
Tacke, M. ;
Pfeifer, D. ;
von Elverfeldt, D. ;
Sevenich, L. ;
Hillebrand, L. E. ;
Kern, U. ;
Sameni, M. ;
Peters, C. ;
Sloane, B. F. ;
Reinheckel, T. .
ONCOGENE, 2014, 33 (36) :4474-4484
[9]   Efficacy results of a phase lb study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+metastatic breast cancer (MBC), including patients (pts) with brain metastases. [J].
Borges, Virginia F. ;
Ferrario, Cristiano ;
Aucoin, Nathalie ;
Falkson, Carla Isadora ;
Khan, Qamar J. ;
Krop, Ian E. ;
Welch, Stephen ;
Bedard, Philippe L. ;
Conlin, Alison Katherine ;
Chaves, Jorge ;
Walker, Luke N. ;
Hamilton, Erika Paige .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10]   Genes that mediate breast cancer metastasis to the brain [J].
Bos, Paula D. ;
Zhang, Xiang H. -F. ;
Nadal, Cristina ;
Shu, Weiping ;
Gomis, Roger R. ;
Nguyen, Don X. ;
Minn, Andy J. ;
van de Vijver, Marc J. ;
Gerald, William L. ;
Foekens, John A. ;
Massague, Joan .
NATURE, 2009, 459 (7249) :1005-U137